AbbVie Market Cap 2010-2024 | ABBV

AbbVie market cap history and chart from 2010 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. AbbVie market cap as of June 14, 2024 is $297.71B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $297.708B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $834.884B 120.67
Novo Nordisk (NVO) Denmark $639.473B 49.14
Johnson & Johnson (JNJ) United States $350.268B 13.91
Merck (MRK) United States $327.948B 59.67
AstraZeneca (AZN) United Kingdom $246.766B 21.45
Novartis AG (NVS) Switzerland $216.092B 15.32
Pfizer (PFE) United States $156.001B 19.39
Sanofi (SNY) $117.002B 11.04
Innoviva (INVA) United States $0.994B 6.98